Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The US Timoptic product line includes Timoptic (timolol maleate) ophthalmic solution, Timoptic (timolol maleate ophthalmic solution) in Ocudose (sterile ophthalmic unit dose dispenser) and Timoptic-XE (timolol maleate ophthalmic gel forming solution) ophthalmic.
Timoptic in Ocudose is believed to be the only preservative-free medication for glaucoma available in the US and aligns with Aton’s strategy of providing unique, medically essential products.
Michael Wells, CEO of Aton Pharma, said: “Aton has made the strategic decision to expand our commitment within the field of ophthalmology. The acquisition of the US Timoptic franchise significantly enhances our profile within the ophthalmology community while enabling us to serve yet another niche market that is greatly underserved.”